Deutsche Bank Maintains a 'Buy' on Dendreon (DNDN): Buyers on Any Weakness
Tweet Send to a Friend
Get Alerts DNDN Hot Sheet
Price: $3.91 -1.01%
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Rating Summary:
5 Buy, 15 Hold, 12 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 19 | Down: 23 | New: 29
Trade DNDN Now!
Deutsche Bank maintains a 'Buy' on Dendreon (NASDAQ: DNDN) price target of $18.00.
Deutsche analyst said, "Johnson & Johnson (NYSE: JNJ) just announced that the Independent Data Monitoring Committee recommended the unblinding of the Zytiga pre-chemo prostate cancer ph 3 trial due to PFS & OS clinical benefit. Placebo patients are now recommended to take Zytiga. JNJ plans to file for FDA approval in H2:12. This is the same indication as Provenge."
"Our view is that hit on interim was expected by many investors. This is more of negative headline risk and we continue to believe current Provenge peak sales of $1.6B ($1.1B in US & $500M in EU) in 2020E are achievable. In our opinion, current DNDN stock price factors in $500M in peak Provenge sales. As per doctor checks, we believe Provenge and Zytiga will be sequenced and both will be used."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.87 yesterday, with a 52 week range of $6.46-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Deutsche analyst said, "Johnson & Johnson (NYSE: JNJ) just announced that the Independent Data Monitoring Committee recommended the unblinding of the Zytiga pre-chemo prostate cancer ph 3 trial due to PFS & OS clinical benefit. Placebo patients are now recommended to take Zytiga. JNJ plans to file for FDA approval in H2:12. This is the same indication as Provenge."
"Our view is that hit on interim was expected by many investors. This is more of negative headline risk and we continue to believe current Provenge peak sales of $1.6B ($1.1B in US & $500M in EU) in 2020E are achievable. In our opinion, current DNDN stock price factors in $500M in peak Provenge sales. As per doctor checks, we believe Provenge and Zytiga will be sequenced and both will be used."
For an analyst ratings summary and ratings history on Dendreon click here. For more ratings news on Dendreon click here.
Shares of Dendreon closed at $10.87 yesterday, with a 52 week range of $6.46-$43.96.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- iPhone Sell-Through Tracking Ahead of Consensus, Says Morgan Stanley (AAPL)
- Canaccord Genuity Boosts Price Target on Akamai (AKAM) Citing Momentum
- Cowen Says Apple (AAPL) No Risk to Uni-Pixel (UNXL)
Create E-mail Alert Related Categories
Analyst Comments, Hot CommentsRelated Entities
Deutsche BankComments
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Prostate Cancer DNDN
Fritz Turton on Mar 8, 2012 10:28 AMMark as Spam | Reply to this comment
Somebody needs to talk to an oncologist specializing in prostate cancer. In short there is no "cure" , only a series of delaying tactics using drugs that fight the cancer using varying strategies . There is a necessity for all three drugs mentioned, not either or.